X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LX1001-01 (AAVrh.10hAPOE2) is an AAV-based investigational gene therapy candidate designed as a one-time treatment delivering a protective APOE2 gene into the CNS for the treatment of APOE4-associated Alzheimer’s disease.
Lead Product(s): AAVrh.10hAPOE2
Therapeutic Area: Neurology Product Name: LX1001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lexeo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 07, 2022
Details:
The collaboration is focused on using [F-18]MK-6240 as a biomarker in neurodegenerative disease drug research and development. The companies will apply [F-18]MK-6240 imaging to evaluate Alnylam’s therapeutic ALN-APP, for the treatment of neurodegenerative diseases.
Lead Product(s): ALN-APP
Therapeutic Area: Neurology Product Name: ALN-APP
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
